Document:

Demerger Deed Poll

 Exhibit 10.14 

 

			
	 Waterfront Place
 1 Eagle Street Brisbane QLD 4000
 GPO Box 9925 QLD 4001

Tel (07) 3228 9333

Fax (07) 3228 9444

www.corrs.com.au
	 	 

 Sydney 
 Melbourne 
 Brisbane 

Perth 
  

 
 Audeo Oncology, Inc. 

 
  
 Deed Poll 
 6897589/6 

 
  
 © Corrs Chambers Westgarth 

 Contents 
  

					
	 1       Interpretation
	  	 	1	  
		
	 1.1        Definitions
	  	 	1	  
		
	 1.2        Construction
	  	 	2	  
		
	 1.3        Headings
	  	 	2	  
		
	 2       Nature of this deed poll
	  	 	2	  
		
	 3       Conditions precedent and termination
	  	 	2	  
		
	 3.1        Conditions precedent
	  	 	2	  
		
	 3.2        Termination
	  	 	2	  
		
	 3.3        Consequences of termination
	  	 	3	  
		
	 4       Certificate in relation to conditions
	  	 	3	  
		
	 5       Audeo Oncology obligations
	  	 	3	  
		
	 5.1        Performance of obligations generally
	  	 	3	  
		
	 5.2        Obligation to update Audeo Oncology Register
	  	 	3	  
		
	 5.3        Confirmation dispatch of holding statements and transaction
confirmations
	  	 	4	  
		
	 6       Audeo Oncology Warrants
	  	 	5	  
		
	 7       Representations and warranties
	  	 	5	  
		
	 8       Continuing obligations
	  	 	6	  
		
	 9       Stamp duty
	  	 	6	  
		
	 10     Notices
	  	 	6	  
		
	 10.1      General
	  	 	6	  
		
	 10.2      How to give a Notice
	  	 	6	  
		
	 10.3      Particulars for delivery of Notices
	  	 	6	  
		
	 10.4      Communications by post
	  	 	7	  
		
	 10.5      Communications by fax
	  	 	7	  
		
	 10.6      After hours communications
	  	 	7	  
		
	 10.7      Process service
	  	 	7	  
		
	 11     General
	  	 	7	  
		
	 11.1      Waiver
	  	 	7	  
		
	 11.2      Cumulative rights
	  	 	8	  
		
	 11.3      Amendment
	  	 	8	  
		
	 11.4      Assignment
	  	 	8	  
		
	 11.5      Severability
	  	 	8	  
		
	 11.6      Further assurances
	  	 	8	  
		
	 11.7      Governing law and jurisdiction
	  	 	8	  

  

			
	6897589/65633423/12	  	 

					
		
	 Schedule 1 – Audeo Oncology Warrant terms
	  	 	9	  
		
	 Schedule 2 – Investors
	  	 	15	  

  

			
	6897589/6	  	page ii

Dated                     
    August 2012 
 By 
 Audeo Oncology, Inc. of 100 Pine Street, Suite 2040, San Francisco, California 94111 (Audeo Oncology) 
 in favour of each Scheme Shareholder and Investor. 
 Background 

 

	A	The directors of Alchemia Limited (Alchemia) consider that it is in the interests of Alchemia and Alchemia’s Shareholders that Alchemia Shareholders
consider the Scheme. The directors of Alchemia have therefore resolved that Alchemia propose the Scheme. 

  

	B	Audeo Oncology and Alchemia have entered into the Demerger Implementation Agreement. 

 

	C	Audeo Oncology is entering into this document for the purpose of covenanting in favour of Scheme Shareholders and the Investors to: 

 

	 	(a)	perform its obligations under the Scheme; and 

  

	 	(b)	issue the Audeo Oncology Warrants to the Investors in accordance with their terms. 

 Declarations 
  

	1	Interpretation 

  

	1.1	Definitions 

 In this
document: 
  

	 	(a)	Audeo Oncology Warrant means an option to subscribe for Audeo Oncology Shares on the terms and conditions set out in schedule 1;

  

	 	(b)	First Tranche Shares means the total number of Alchemia Shares available for placement under the first tranche of the Placement; 

 

	 	(c)	Investors means the persons and entities who have a right to receive Audeo Oncology Warrants as set out in schedule 2; 

 

	 	(d)	Listing means the listing of Audeo Oncology on a securities exchange; 

  

			
	6897589/65633423/12	  	page 1

	 	(e)	Placement means the Alchemia institutional placement capital raising in November 2011 to be undertaken in two tranches; 

 

	 	(f)	Second Tranche Shares means the balance of Alchemia Shares to be issued under the Placement; and 

 

	 	(g)	words and phrases defined in the Scheme have the same meaning in this document unless the context requires otherwise. 

 

	1.2	Construction 

 The rules
specified in clause 1.2 of the Scheme apply in interpreting or construing this document, unless the context requires otherwise. 
  

	1.3	Headings 

 Headings do not
affect the interpretation of this document. 
  

	2	Nature of this deed poll 

 Audeo
Oncology acknowledges that: 
  

	 	(a)	this document may be relied on and enforced by any Scheme Shareholder or Investor in accordance with its terms, even though the Scheme Shareholders and Investors are
not party to it; and 

  

	 	(b)	under the Scheme, each Scheme Shareholder irrevocably appoints Alchemia and any of Alchemia’s directors as its agent and attorney, inter alia, to enforce this
document against Audeo Oncology. 

  

	3	Conditions precedent and termination 

  

	3.1	Conditions precedent 

 The
obligations of Audeo Oncology in respect of the Scheme pursuant to this document are subject to the Scheme becoming Effective and the satisfaction of the Condition Subsequent by the End Date. 

 

	3.2	Termination 

 If:

  

	 	(a)	the Demerger Implementation Agreement is terminated in accordance with its terms before 8.00 am on the Second Court Date; 

 

	 	(b)	the Conditions are not satisfied or waived by the time required; 

  

	 	(c)	the Condition Subsequent is not satisfied by the End Date; or 

  

	 	(d)	the Effective Date has not occurred on or before the End Date, 

 Audeo Oncology’s obligations under this document will automatically terminate, unless Audeo Oncology and Alchemia otherwise agree in writing in accordance with the Demerger Implementation Agreement.

  

			
	6897589/6	  	page 2

	3.3	Consequences of termination 

 If this document is terminated under clause 3.2 then, in addition and without prejudice to any other rights, powers or remedies available to Scheme Shareholders: 

 

	 	(a)	Audeo Oncology is released from its obligations to further perform this document, except those obligations contained in clause 9; and

  

	 	(b)	each Scheme Shareholder and Investor retains any rights, power or remedies it has against Audeo Oncology in respect of any breach of this document by Audeo Oncology
which occurred before termination of this document. 

  

	4	Certificate in relation to conditions 

 Audeo Oncology must provide to the Court on the Second Court Date a certificate which is authorised by the board of Audeo Oncology and signed by at least one director of Audeo Oncology (or such other
evidence as the Court may request) stating, to the best of its knowledge, whether or not the conditions precedent set out in clause 3.1 (other than clause 3.1(e)) of the Scheme have been satisfied or waived, subject to the terms of the Demerger
Implementation Agreement as at 8.00 am on the Second Court Date. 
  

	5	Audeo Oncology obligations 

  

	5.1	Performance of obligations generally 

 Subject to clause 3, Audeo Oncology must comply with its obligations under the Demerger Implementation Agreement and must do all things necessary or desirable on its part to implement the Scheme.

  

	5.2	Obligation to update Audeo Oncology Register 

 As soon as practicable after the Implementation Date, Audeo Oncology must enter, or procure the entry, into the Audeo Oncology Register of: 

 

	 	(a)	each Scheme Shareholder (other than Ineligible Foreign Shareholders) or CDN (as relevant) in respect of the Audeo Oncology Shares transferred to the relevant Scheme
Shareholder or CDN (as relevant) under the Scheme; 

  

	 	(b)	each Scheme Shareholder (other than Ineligible Foreign Shareholders) in respect of the Audeo Oncology CDIs issued to the relevant Scheme Shareholder under the Scheme;
and 

  

	 	(c)	the Sale Facility Agent, as nominee for and on behalf of, the Ineligible Foreign Shareholders, in respect of the Audeo Oncology Shares or Audeo Oncology CDIs to which
those shareholders are entitled to under the Scheme. 

  

			
	6897589/6	  	page 3

	5.3	Confirmation dispatch of holding statements and transaction confirmations 

 

	 	(a)	In accordance with clauses 4.6 and 4.7 of the Scheme, as soon as practicable after the Implementation Date, Audeo Oncology must send: 

 

	 	(i)	to Scheme Shareholders that are entitled to and elect to receive Audeo Oncology Shares, transaction confirmations for the Audeo Oncology Shares to which they are
entitled; 

  

	 	(ii)	for Ineligible Foreign Shareholders: 

  

	 	(A)	to CDN, as the nominee for the Sale Facility Agent, transaction confirmations for the Audeo Oncology Shares which that Ineligible Foreign Shareholder would otherwise be
entitled; and 

  

	 	(B)	to the Sale Facility Agent as nominee for the Ineligible Foreign Shareholders, holding statements for the Audeo Oncology CDIs to which that Ineligible Foreign
Shareholder would otherwise be entitled; and 

  

	 	(iii)	for all other Scheme Shareholders: 

  

	 	(A)	to CDN as nominee for that Scheme Shareholder, transaction confirmations for the Audeo Oncology Shares to which that Scheme Shareholder would otherwise be entitled; and

  

	 	(B)	to that Scheme Shareholder, holding statements for the Audeo Oncology CDIs to which that Scheme Shareholder would otherwise be entitled, 

by prepaid post (in the case of holding statements) or first class post (in the case of transaction confirmations) to: 

 

	 	(iv)	in the case of Scheme Shareholders, their Registered Addresses, unless that Scheme Shareholder has directed otherwise, does not have a Registered Address or where
Alchemia and Audeo Oncology believe that such Scheme Shareholder is not known at their Registered Address; 

  

	 	(v)	in the case of the Sale Facility Agent, the address notified to Alchemia by the Sale Facility Agent; and 

 

	 	(vi)	in the case of CDN, the address notified to Alchemia by CDN. 

  

	 	(b)	In the case of Scheme Shares held in joint names: 

  

	 	(i)	any share certificates for Audeo Oncology Shares or holding statements for Audeo Oncology CDIs to be issued to Scheme Shareholders will be issued in the names of the
joint holders; and 

  

	 	(ii)	any cheque required to be paid to Ineligible Foreign Shareholders will be payable to the joint holders, and will be forwarded to the holder whose name appears first in
the Alchemia Register as at the Scheme Record Date. 

  

			
	6897589/6	  	page 4

	 	(c)	This clause 5.3 does not apply to a Scheme Shareholder (other than Ineligible Foreign Shareholders) who does not have a Registered Address, or where Alchemia and
Audeo Oncology believe that such Scheme Shareholder is not known at their Registered Address. 

  

	6	Audeo Oncology Warrants 

Subject to the listing of Audeo Oncology on NASDAQ on or before 31 December 2012, Audeo Oncology must as soon as practicable after
Audeo Oncology is admitted to NASDAQ: 
  

	 	(a)	issue to each Investor; and 

  

	 	(b)	register each Investor as the holder of, 

 the number of Audeo Oncology Warrants (based on each Audeo Oncology Warrant entitling the Investor to subscribe for an Audeo Oncology Share) calculated as follows: 

 
 

 
 where: 
 a = Audeo Oncology Warrants; 
 b = 50% of the aggregate subscription price for the
First Tranche Shares and the Second Tranche Shares (if any) subscribed for by the Investor; and 
 c = 130% of the volume
weighted average price of Audeo Oncology Warrants over the 60 trading days immediately following Listing. 
  

	7	Representations and warranties 

 Audeo Oncology represents and warrants that: 
  

	 	(a)	it is a company validly existing under the laws of Delaware, the United States; 

 

	 	(b)	it has the corporate power to enter into and perform its obligations under this document and to carry out the transactions contemplated by this document;

  

	 	(c)	it has taken all necessary corporate action to authorise the entry into this document and has taken or will take all necessary corporate action to authorise the
performance of this document and to carry out the transactions contemplated by this document; 

  

	 	(d)	this document is its valid and binding obligation enforceable in accordance with its terms; and 

  

			
	6897589/6	  	page 5

	 	(e)	the Audeo Oncology Shares to be issued pursuant to the Scheme will be validly issued, fully paid and free from any mortgage, charge, lien, encumbrance or other security
interest and will rank equally in all respects with all other Audeo Oncology Shares then on issue. 

  

	8	Continuing obligations 

This document is irrevocable and, subject to clause 3, remains in full force and effect until: 

 

	 	(a)	Audeo Oncology has completely performed its obligations under this document and the Demerger Implementation Agreement; or 

 

	 	(b)	this document is terminated in accordance with clause 3, 

 whichever comes first. 
  

	9	Stamp duty 

 Audeo
Oncology will: 
  

	 	(a)	pay all stamp duties and any related fines, interest and penalties in respect of or in connection with this document, the performance of this document and each
transaction effected by or made or any instrument executed under this document or the Scheme, including the transfer of Scheme Shares under the Scheme; and 

 

	 	(b)	indemnify each Scheme Shareholder on demand against any liability arising from its failure to comply with clause 9(a). 

 

	10	Notices 

  

	10.1	General 

 Any notice,
transfer, transmission, application, direction, demand, consent or other communication (Notice) given or made to Audeo Oncology under this document must be in writing in English and signed by the sender or a person duly authorised by the
sender. 
  

	10.2	How to give a Notice 

 A Notice must be given to Audeo Oncology by being: 
  

	 	(a)	personally delivered; 

  

	 	(b)	left at Audeo Oncology’s current delivery address for notices; 

  

	 	(c)	sent to Audeo Oncology’s current postal address for notices by pre-paid ordinary mail or, if the address is outside Australia, by pre-paid airmail; or

  

	 	(d)	sent by fax to Audeo Oncology’s current fax number for notices. 

  

	10.3	Particulars for delivery of Notices 

 The particulars for delivery of Notices to Audeo Oncology are: 

  

			
	6897589/6	  	page 6

					
	 Attention:
	  	Tracie Ramsdale	  	
	 Delivery address:
	  	3 Hi Tech Court, Eight Mile Plains	  	
		  	Brisbane Queensland 4113	  	
	 Postal address:
	  	Same as delivery address	  	
	 Fax:
	  	+61 7 3340 0222	  	

  

	10.4	Communications by post 

Subject to clause 10.6, a Notice is given if posted: 

 

	 	(a)	within Australia to an Australian postal address, three Business Days after posting; or 

 

	 	(b)	outside of Australia to an Australian postal address or within Australia to an address outside of Australia, ten Business Days after posting.

  

	10.5	Communications by fax 

Subject to clause 10.6, a Notice is given if sent by fax, when the sender’s fax machine produces a report that the fax
was sent in full to the addressee. That report is conclusive evidence that the addressee received the fax in full at the time indicated on that report. 
  

	10.6	After hours communications 

If a Notice is given: 
  

	 	(a)	after 5.00 pm in the place of receipt; or 

  

	 	(b)	on a day which is a Saturday, Sunday or bank or public holiday in the place of receipt, 

it is taken as having been given at 9.00 am on the next day which is not a Saturday, Sunday or bank or public holiday in that place.

  

	10.7	Process service 

 Any
process or other document relating to litigation, administrative or arbitral proceedings relating to this document may be served by any method contemplated by this clause 10 or in accordance with any applicable law. 

 

	11	General 

  

	11.1	Waiver 

 Failure to
exercise or enforce or a delay in exercising or enforcing or the partial exercise or enforcement of any right, power or remedy provided by law or under this document by any party will not in any way preclude, or operate as a waiver of, any exercise
or enforcement, or further exercise or enforcement of that or any other rights, power or remedy provided by law or under this document. A waiver is not valid or binding on the person granting that waiver unless made in writing. 

  

			
	6897589/6	  	page 7

	11.2	Cumulative rights 

 The
rights, powers and remedies of Audeo Oncology and of each Scheme Shareholder and Investor under this document are cumulative and do not exclude any other rights, powers or remedies provided by law or equity independently of this document.

  

	11.3	Amendment 

 A provision of
this document may not be varied unless: 
  

	 	(a)	if before the First Court Date, the variation is agreed to by Alchemia; or 

 

	 	(b)	if on or after the First Court Date, the variation is agreed to by Alchemia and the Court indicates that the variation would not of itself preclude approval of the
Scheme, 

 in which event Audeo Oncology must enter into a further deed poll in favour of the Scheme Shareholders
and Investors giving effect to that amendment. 
  

	11.4	Assignment 

 The rights
and obligations of Audeo Oncology and of each Scheme Shareholder and Investor under this document are personal and must not be assigned, encumbered or otherwise dealt with at law or in equity and no person may attempt, or purport, to do so without
the prior written consent of Audeo Oncology and Alchemia. 
  

	11.5	Severability 

 If the
whole or any part of a provision of this document is void, unenforceable or illegal in a jurisdiction it is severed for that jurisdiction. The remainder of this document has full force and effect and the validity or enforceability of that provision
in any other jurisdiction is not affected. This clause 11.5 has no effect if the severance alters the basic nature of this document or is contrary to public policy. 

 

	11.6	Further assurances 

 Audeo
Oncology will execute and deliver all documents and do all acts and things (on its own behalf and on behalf of each Scheme Shareholder and Investor) necessary or desirable to give full effect to this document and the transactions contemplated by it.

  

	11.7	Governing law and jurisdiction 

  

	 	(a)	This document is governed by and is to be construed in accordance with the laws applicable in Queensland, Australia. 

 

	 	(b)	Each party irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts exercising jurisdiction in Queensland, Australia, and any courts
which have jurisdiction to hear appeals from any of those courts, and waives any right to object to any proceedings being brought in those courts. 

  

			
	6897589/6	  	page 8

 Schedule 1 
  

	 	a.	Each warrant entitles the holder to subscribe for a fully paid share of common stock of Audeo Oncology, Inc. (the “Company”) (a
“Share”) upon exercise of the warrant and payment of the Exercise Price (defined below). 

  

	 	b.	Each warrant is exercisable for shares of common stock at an exercise price equal to 130% of the volume weighted average price of the Shares over the 60 trading days
immediately following the listing of the Company on a recognised securities exchange (the “Exercise Price”), payable in full on exercise of the warrant. 

 

	 	c.	The warrants vest and are exercisable from the date that is six months after the date of the initial public offering of the Company (the “IPO Date”)
until the date that is the later to occur of the following (the “Expiry Date”): 

  

	 	(i)	three years from IPO Date; and 

  

	 	(ii)	the earlier of: 

  

	 	(A)	six months from the date that the Company announces to the market the results for the primary end point of the Phase III clinical trial period for HA-Irinotecan in
colorectal cancer; and 

  

	 	(B)	five years from the IPO Date. 

 Any warrant not exercised prior to the Expiry Date, automatically expires on the Expiry Date. 
  

	 	d.	The Company must give the holder of each warrant a certificate or holding statement including these warrant terms and stating: 

 

	 	(i)	the number of warrants issued to each holder; 

  

	 	(ii)	the Exercise Price of the warrants; and 

  

	 	(iii)	the date of issue of the warrants. 

  

	 	e.	Warrants may only be exercised by the delivery to the registered office of the Company or its share registry of a certificate in the form attached as annexure A to
these warrant terms and a notice (the “Exercise Notice”) in writing stating the intention of the holder to: 

  

	 	(i)	exercise all or a specified number of warrants; and 

  

	 	(ii)	either pay the Exercise Price in cash for the exercise of each such warrant or elect a cashless exercise for the exercise of each such warrant.

  

	 	f.	The Exercise Notice must be accompanied by the certificate or holding statement for the warrants being exercised, if not a cashless exercise, and a cheque made payable
to the Company for the Exercise Price for the warrants being exercised. 

  

	 	g.	In lieu of paying the Exercise Price in cash for the exercise of each warrant, if the fair market value of one share of common stock is greater than the Exercise Price,
the holder may elect a cashless exercise of the warrant. 

  

	 	h.	The warrants will be deemed to have been exercised on the date the Exercise Notice is received by the Company or the share registry. 

 

	 	i.	The Company will allot the Shares to which a holder is entitled following exercise of warrants and deliver a holding statement with respect to such Shares within the
timeframe required by the listing rules of the exchange on which the Company is listed. 

  

			
	6897589/6	  	page 9

	 	j.	The exercise of only some portion of a warrant will not affect the rights of the holder to the balance of the warrants held by them. 

 

	 	k.	If the holder of the warrants exercises less than the total number of warrants registered in the holder’s name: 

 

	 	(i)	the holder of the warrants must surrender its warrant certificate, if one has been issued by the Company; and 

 

	 	(ii)	the Company must cancel the warrant and issue the holder of the warrants a new warrant or holding statement stating the remaining number of warrants held by the holder
and stating the information set out in item (d) above. 

  

	 	l.	Warrants will not confer an entitlement to receive dividends declared and paid by the Company, nor an entitlement to vote at general meetings of the Company unless the
holder of the warrants has exercised its warrants before the record date for determining these entitlements and participates as a result of holding Shares. 

 

	 	m.	Each Share issued on exercise of an warrant will: 

  

	 	(i)	rank equally in all respects (including, without limitation, rights relating to dividends) with other issued Shares; 

 

	 	(ii)	be issued credited as fully paid; 

  

	 	(iii)	be duly authorised and issued by all necessary corporate action; and 

  

	 	(iv)	be allotted and issued free from all liens, charges and encumbrances whether known about or not including statutory and other pre-emption rights and any transfer
restrictions. 

  

	 	n.	The Company will apply to the exchange on which the Company is listed for official quotation of the Shares issued upon exercise of warrants within the time period
required by the listing rules of the exchange on which the Company is listed. 

  

	 	o.	The warrants are not transferable without the prior written consent of the Company, which shall not be unreasonably withheld only where all warrants held by the holder
are transferred to a related body corporate of the holder (or, in the case of a custodian of a fund, a custodian of a fund with the same manager), that: 

  

	 	(i)	the Company is satisfied (acting reasonably) is a permitted transferee under applicable securities law without additional disclosure or other regulatory requirements on
either the transferor or the Company; 

  

	 	(ii)	has provided any written certification or other evidence of their sophisticated/professional/exempt investor status, reasonably requested by the Company; and

  

	 	(iii)	has agreed in writing to be bound by these warrant terms (including, if required by the Company, delivering a certificate in the form attached as annexure A to these
warrant terms on exercise of the warrants). 

  

	 	p.	A holder of warrants does not have the right to participate in bonus issues or new issues of securities offered to shareholders until Shares are allotted to the holder
pursuant to the exercise of the relevant warrants. 

  

			
	6897589/6	  	page 10

	 	q.	After the listing of the Company on a securities exchange, and in the event of a reorganisation (including, without limitation, consolidation, sub-division, reduction
or return) of the capital of the Company, the rights of the holders of warrants (including, without limitation, the number of warrants to which the warrant holder is entitled and the exercise price) will be changed (as appropriate) in accordance
with the listing rules of the exchange on which the Company is listed applying to a reorganisation of capital at the time of the reorganisation. 

  

	 	r.	If after the listing of the Company on a securities exchange, the Company makes a pro rata issue (other than a bonus issue) to existing shareholders and no Shares have
been issued in respect of the warrants before the record date for determining entitlements to the issue, the Exercise Price of each warrant will be reduced in the manner permitted by the listing rules of the exchange on which the Company is listed.

  

	 	s.	If after the listing of the Company on a securities exchange, the Company makes a bonus issue to existing shareholders and no Share has been issued in respect of a
warrant before the record date for determining entitlements to the issue, then the number of Shares over which that warrant is exercisable will be increased in the manner permitted by the listing rules of the exchange on which the Company is listed.

  

	 	t.	The Company is entitled to treat the registered holder of a warrant as the absolute holder of that warrant and is not bound to recognise any equitable or other claim
to, or interest in, that warrant on the part of any person other than the registered holder, except as ordered by a court of competent jurisdiction or as required by statute. 

 

	 	u.	If the Company is obliged to make a payment in respect of withholding tax in relation to the warrants, the Company must: 

 

	 	(i)	promptly pay any amount deducted to the appropriate governmental taxation authority; 

 

	 	(ii)	if requested by the warrant holder, within 30 days after that request, give to that warrant holder a copy of the relevant documentation evidencing the payment; and

  

	 	(iii)	issue the warrant holder the net number of warrants after making the payment. 

  

			
	6897589/6	  	page 11

 Annexure A 
 Certificate for warrant holders 
 By executing this Investor Certificate in favour of Audeo
Oncology, Inc. (the “Company”), the undersigned (“holder”) represents, warrants and covenants to the Company, and acknowledges that the Company is relying thereon, that: 

 

	(a)	if the YES box is checked, it is not a U.S. person and is not acquiring the securities for the benefit of any U.S. person; 

YES
   ̈    No   ̈ 
  

	(b)	if the YES box is checked, it is an institutional “Accredited Investor” as defined in Rule 501(a)(1), (2) (3) or (7) under the U.S. Securities
Act of 1933, as amended (the “1933 Act”); 

 YES
   ̈    No   ̈ 
  

	(c)	it understands that the shares of common stock of the Company (the “Shares”) to be issued upon exercise of the warrants (the
“Warrants”) have not been (and will not be) registered under the 1933 Act or any applicable state securities laws, and that the contemplated issue of Shares is being made in reliance on a private placement exemption available under
the 1933 Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the holder’s representations, warranties and covenants as expressed herein and the Company is under no obligation to register
any subsequent proposed resale of the shares by the holder; and the holder agrees not to engage in hedging transactions with regard to such Shares unless in compliance with the Act: 

 

	(d)	it understands that the issue of Shares on exercise of a Warrant is not intended to be part of a public offering and that it will not be able to rely on the protection
of Section 11 of the 1933 Act; 

  

	(e)	it is acquiring the Shares for its own account and not with a view to any resale, distribution or other disposition (to the extent possible) of the Shares in violation
of U.S. federal or state securities laws, and it is not an underwriter with respect to the Shares within the meaning of Section 2(a) (11) of the 1933 Act; 

 

	(f)	it has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the issue of Shares on exercise of a
Warrant with the Company’s management and has had access to such additional information, if any, concerning the Company as it has considered necessary or appropriate in connection with its investment decision to exercise the Warrants;

  

	(g)	it is aware of the characteristics of the Shares, the risks relating to an investment therein and agrees that the holder must bear the economic risk of its investment
in the Shares and the holder acknowledges that it can bear the economic risk of its investment and is able, without impairing its financial condition, to hold the Shares for an indefinite period of time and to suffer a complete loss of its
investment;

  

	(h)	it alone, or with the assistance of its professional advisors, has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks
of the holder’s proposed investment in the Shares; 

  

			
	6897589/6	  	page 12

	(i)	it agrees that if it decides to sell or otherwise transfer (to the extent possible) any Shares, it will only do so only if the offer and sale (to the extent possible)
of such Shares is (i) registered under the 1933 Act (which the holder acknowledges the Company has no obligation to do); (ii) made pursuant to an exemption from registration under the Act, or (iii) made in standard (regular way)
brokered transactions on the exchange on which the Shares are listed, provided that such exchange is a “designated offshore securities market” as defined in Regulation S under the 1933 Act (“Regulation S”)
(“Exchange”) in offshore transactions that qualifies for the exemption available under Regulation S where neither it nor any person acting on its behalf knows, or has reason to know, that the sale has been pre-arranged with, or that
the purchaser is, a person in the United States; 

  

	(j)	it is not engaged in the business of distributing securities or, if it is, it agrees that it will not offer or sell in the United States (i) any Shares it acquires
at any time or (ii) any ordinary shares of the Company that it may acquire other than as a result of exercising Warrants until one year after the relevant date of issue or transfer, except in either of cases (i) or (ii), in a transaction
exempt from the registration requirements of the 1933 Act. Notwithstanding the foregoing, it may sell Shares in standard (regular way) brokered transactions on the Exchange in offshore transactions in accordance with Regulation S where neither it
nor any person acting on its behalf knows, or has reason to know, that the sale has been pre-arranged with, or that the purchaser is, a person in the United States; 

 

	(k)	it understands that the Shares will constitute “restricted securities” within the meaning of Rule 144(a)(3) under the 1933 Act and it will not deposit such
Shares into any unrestricted depositary receipt facility established or maintained by a depositary bank unless and until such time as such Shares are no longer “restricted securities” within the meaning of Rule 144(a)(3) of the 1933 Act;

  

	(l)	it is not acquiring the Shares as a result of any “general solicitation or general advertising” (as those terms are used in Regulation D under the 1933 Act),
including, but not limited to, any advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or on the Internet or broadcast over radio, television or the Internet, or any seminar or meeting
whose attendees have been invited by general solicitation or general advertising, and it has a pre-existing business relationship with the Company; 

  

	(m)	it is aware that (i) acquiring, holding and disposing (to the extent possible) of the Shares may have tax consequences under the laws of both Australia and the
United States and (ii) it is solely responsible for determining the tax consequences applicable to its particular circumstances and should consult its own tax advisors concerning investment in such securities; 

 

	(n)	if the holder is an employee benefit plan but is not an investor which is subject to the prohibited transaction rules of Section 4975 of the U.S. Internal Revenue
Code of 1986 (the “Code”) or the fiduciary responsibility provisions of the U.S. Employee Retirement Security Act of 1974 (“ERISA”) (such an investor, a “Benefit Plan Investor”), the acquisition and
holding of the Shares by the holder complies with all applicable laws governing the holder, is in accordance with the holder’s governing documents, and will not result in the assets of the Company being treated as the “plan assets” of
the holder under applicable law; 

  

	(o)	 if the holder is a Benefit Plan Investor, (i) the holder’s commitment to purchase the Shares does not, in the aggregate, constitute more than
10% of the fair market value of the holder’s assets, (ii) the acquisition and holding of the Shares by the holder complies with all applicable requirements of ERISA, the Code and other

  

			
	6897589/6	  	page 13

	 	
applicable laws governing the holder and is in accordance with the holder’s governing documents, (iii) the acquisition and holding of the Shares by the holder either does not constitute
a prohibited transaction under Section 406 of ERISA or Section 4975 of the Code, or one or more statutory or administrative exemptions from the prohibited transaction rules of ERISA and the Code is applicable to such acquisition and
holding and (iv) the holder agrees to provide to the Company, in writing, all additional information that the Company may reasonably request in order to avoid violations of any provision of ERISA and to determine whether the holder meets the
suitability standards for ownership of the Shares; and 

  

	(p)	it agrees that the Warrants have been issued to it in satisfaction in full of Alchemia Limited’s or Alchemia Oncology Pty Ltd’s obligation (if any) to issue
options to you under the subscription agreement between you and Alchemia Limited and Alchemia Oncology Pty Ltd dated on or about 5 November 2011. 

 Details of holder and authorised signatory 

Holder:                        
                                         
                                         
                                         
                                         
                                         
              

Signature (authorised signatory):                  
                    Date:                   
                                         
                                         
                                       

Name:                        
                                         
                                         
                                         
                                         
                                         
                

Title:                        
                                         
                                         
                                         
                                         
                                         
                   

  

			
	6897589/6	  	page 14

 Schedule 2 
 Investors 
  

			
	1.	  	ABN AMRO CLEARING SYDNEY
	2.	  	ANTIOCH INVESTMENTS AUSTRALIA
	3.	  	ARMADA TRADING PTY LIMITED
	4.	  	ASIA UNION INVESTMENTS
	5.	  	AUST EXECUTOR TRUSTEES NSW LTD
	6.	  	BERNE NO 132 NOMINEES PTY LTD
	7.	  	BERNE NO 132 NOMINEES PTY LTD
	8.	  	BERNE NO 132 NOMINEES PTY LTD
	9.	  	BOUSSAL PTY LTD
	10.	  	BRYLET PTY LIMITED
	11.	  	C B C SECURITIES PTY LIMITED
	12.	  	CAWDOR-CRAIGNISH PTY LTD
	13.	  	CITICORP NOMINEES PTY LIMITED
	14.	  	CLEM JONES PTY LTD
	15.	  	CRAIMAR INVESTMENTS PTY
	16.	  	DEHORS HOLDINGS PTY LTD
	17.	  	DR BRIAN HARRY LOCKHART GIBSON
	18.	  	DR SIAVASH ES’HAGHI &
	19.	  	ELSCLIFF PTY LTD
	20.	  	GILLILODGE PTY LIMITED
	21.	  	GREENWICH STREET PTY LTD
	22.	  	HARBURG NOMINEES PTY LTD
	23.	  	HATTONGROVE PTY LTD
	24.	  	HSBC CUSTODY NOMINEES
	25.	  	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED-GSCO ECA
	26.	  	INDLETRAN PTY LIMITED
	27.	  	J P MORGAN NOMINEES AUSTRALIA
	28.	  	JAGEN PTY LTD
	29.	  	JP MORGAN NOMINEES AUSTRALIA
	30.	  	JULIBER PTY LTD
	31.	  	LALIBER PTY LTD
	32.	  	LITTLE OWL CAPITAL PTY LTD
	33.	  	M E J C PTY LTD
	34.	  	MAXIM SUPER FUND PTY LTD
	35.	  	MISS JOSEPHINE MYRA LITTLE
	36.	  	MITCHELLDANGAR PTY LTD
	37.	  	MIZPOCHA PTY LTD
	38.	  	MONTOYA PTY LTD
	39.	  	MR ANDREW GEORGE MALUISH &
	40.	  	MR ANTHONY STEPHEN WALL &
	41.	  	MR BRIAN GERARD SHEAHAN
	42.	  	MR CONSTANTINE CHRISTOFIDES &
	43.	  	MR DALLAS JOHN WILLIAM ALLMAN
	44.	  	MR DARREN JOHN THOMPSON &
	45.	  	MR DAVID FREDERICK OAKLEY

  

			
	6897589/6	  	page 15

			
	46.	  	MR DEREK ROBERT MC COMBER &
	47.	  	MR GREGORY WAYNE BROWN
	48.	  	MR JAMES MARK STEPHANOS &
	49.	  	MR JAMIE PHEROUS
	50.	  	MR JOHN WIEN-SMITH
	51.	  	MR LEGH DAVIS &
	52.	  	MR MATTHEW EDWARD CLARKE
	53.	  	MR NIGEL PAUL ST CLAIR EMSLIE
	54.	  	MR PAUL ROSS NUTTER &
	55.	  	MR PETER JAMES COLEMAN &
	56.	  	MR PETER RONALD MORRISON &
	57.	  	MR PHILIP ANDREW THICK
	58.	  	MR PHILIP JOHN LEE &
	59.	  	MR ROGER WILLIAM LEANING
	60.	  	MR SCOTT WILLIAM DUGGAN &
	61.	  	MR SCOTT WILLIAM POWER &
	62.	  	MR SIMON PETER FERGUSON &
	63.	  	MR THOMAS WILLIAM MAlchemiaEAN
	64.	  	MRS FIONA RICHARDSON
	65.	  	MRS GAIL IRENE WISSEMANN
	66.	  	MRS KAREN GRETA MARTIN
	67.	  	MRS LORRAINE DAWN HAYDEN
	68.	  	MRS LOTTE KATRINA TURLEY
	69.	  	MRS VIOLETA TODOROVA
	70.	  	NATIONAL NOMINEES LIMITED
	71.	  	NILIBER PTY LTD
	72.	  	PAWGRIF PTY LTD
	73.	  	PHILLIP ASSET MANAGEMENT LTD
	74.	  	PINWILLOW PTY LTD
	75.	  	PLANETTE THOROUGHBRED TRADING
	76.	  	PLASMA EQUITIES RESEARCH PTY
	77.	  	REDLICH SUPERANNUATION FUND
	78.	  	RESHAPE PTY LTD
	79.	  	ROSHERVILLE PTY LTD
	80.	  	S G TURLEY NOMINEES PTY LTD
	81.	  	T B I C PTY LTD
	82.	  	THE TRUST COMPANY
	83.	  	TIMBINA PTY LTD
	84.	  	TRINA INVESTMENTS PTY LTD
	85.	  	TROPICAL HARVEST PTY LTD
	86.	  	UBS NOMINEES PTY LTD
	87.	  	VANDALEX PTY LTD
	88.	  	X F INVESTMENTS PTY LTD

  

			
	6897589/6	  	page 16

 Executed as a deed poll in Queensland, Australia. 

 

	
	Executed by Audeo Oncology, Inc.
	
	/s/ Charles Walker
	Signature
	
	 Charles Walker

	by (print name)
	
	 Chief Financial Officer

	its (print title)

  

			
	6897589/6	  	page 172012 Stock Plan

 Exhibit 10.16 
 AUDEO ONCOLOGY, INC. 
 2012 STOCK PLAN 

1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for
positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. Options granted under the Plan may be Incentive Stock Options or Nonstatutory
Stock Options, as determined by the Administrator at the time of grant. 
 2. Definitions. As used herein, the following
definitions shall apply: 
 (a) “Administrator” means the Board or any of its Committees as shall be
administering the Plan in accordance with Section 4 hereof. 
 (b) “Applicable Laws” means the
requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Company or the Common Stock or interests
relating to the Common Stock is listed or quoted and the applicable laws of any other country or jurisdiction where Awards are, or will be, granted under the Plan, including the ASX Listing Rules. 

(c) “ASX Listing Rules” means the listing rules of ASX Limited. 

(d) “Award” means, individually or collectively, a grant under the Plan of Options. 

(e) “Board” means the Board of Directors of the Company. 

(f) “Change in Control” means the occurrence of any of the following events: 

(i) Change in Ownership of the Company. A change in the ownership of the Company which occurs on the date that any one person, or
more than one person acting as a group (“Person”), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company,
except that any change in the ownership of the stock of the Company as a result of a private financing of the Company that is approved by the Board will not be considered a Change in Control; or 

(ii) Change in Effective Control of the Company. If the Company has a class of securities registered pursuant to Section 12
of the Exchange Act, a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by
a majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by
the same Person will not be considered a Change in Control; or 

 (iii) Change in Ownership of a Substantial Portion of the Company’s Assets. A
change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such
person or persons) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For
purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. 

For purposes of this Section 2(e), persons will be considered to be acting as a group if they are owners of a corporation that
enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. 

Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in
control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated
thereunder from time to time. 
 Further and for the avoidance of doubt, a transaction will not constitute a Change in Control
if: (i) its sole purpose is to change the jurisdiction of the Company’s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the
Company’s securities immediately before such transaction. 
 (g) “Code” means the Internal Revenue Code of
1986, as amended. Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code. 
 (h) “Committee” means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or by the Compensation Committee of the Board, in accordance with
Section 4 hereof. 
 (i) “Common Stock” means the Common Stock of the Company. 

(j) “Company” means Audeo Oncology, Inc., a Delaware corporation, or any successor thereto. 

(k) “Consultant” means any person who is engaged by the Company or any Parent or Subsidiary to render consulting or
advisory services to such entity. 
 (l) “Director” means a member of the Board. 

  
 -2-

 (m) “Disability” means total and permanent disability as defined in
Section 22(e)(3) of the Code. 
 (n) “Employee” means any person, including officers and Directors,
employed by the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director’s fee by the Company shall be sufficient to constitute “employment” by the Company. 

(o) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(p) “Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange
for Awards of the same type (which may have lower or higher exercise prices and different terms), awards of a different type, and/or cash, (ii) Optionees would have the opportunity to transfer any outstanding Awards to a financial institution
or other person or entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Award is reduced or increased. The terms and conditions of any Exchange Program will be determined by the Administrator in its sole
discretion. 
 (q) “Fair Market Value” means, as of any date, the value of Common Stock determined as follows:

 (i) If the Common Stock is listed on any established stock exchange or a national market system, including without
limitation the Nasdaq Global Market, the Nasdaq Global Select Market or the Nasdaq Capital Market of The Nasdaq Stock Market, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as
quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 
 (ii) If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, its Fair Market Value shall be the mean between the high bid and low asked prices for
the Common Stock on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported in The Wall Street Journal or such other source as the
Administrator deems reliable; or 
 (iii) In the absence of an established market for the Common Stock, the Fair Market Value
thereof shall be determined in good faith by the Administrator. 
 (r) “Incentive Stock Option” means an Option
that by its terms qualifies and is otherwise intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder. 

(s) “Nonstatutory Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an
Incentive Stock Option. 
 (t) “Option” means a stock option granted pursuant to the Plan. 

  
 -3-

 (u) “Option Agreement” means a written or electronic agreement between the
Company and an Optionee evidencing the terms and conditions of an individual Option grant. The Option Agreement is subject to the terms and conditions of the Plan. 
 (v) “Optionee” means the holder of an outstanding Award granted under the Plan. 
 (w) “Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Section 424(e) of the Code. 

(x) “Plan” means this 2012 Stock Plan. 
 (y) “Securities Act” means the Securities Act of 1933, as amended. 
 (z) “Service Provider” means an Employee, Director or Consultant. 

(aa) “Share” means a share of the Common Stock, as adjusted in accordance with Section 11 below. 

(bb) “Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in
Section 424(f) of the Code. 
 3. Stock Subject to the Plan. Subject to the provisions of
Section 8 of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold under the Plan is 948,000 Shares. In no event shall the number of Shares issued pursuant to Incentive Stock Options exceed 948,000 Shares. The
Shares may be authorized but unissued, or reacquired Common Stock. 
 If an Award expires or becomes unexercisable without
having been exercised in full, or is surrendered pursuant to an Exchange Program, the unpurchased Shares that were subject thereto shall become available for future grant or sale under the Plan (unless the Plan has terminated). However, Shares that
have actually been issued under the Plan, upon exercise of an Award, shall not be returned to the Plan and shall not become available for future distribution under the Plan. 
 4. Administration of the Plan. 
 (a) Administrator.
The Plan shall be administered by the Board or a Committee appointed by the Board, which Committee shall be constituted to comply with Applicable Laws. 
 (b) Powers of the Administrator. Subject to the provisions of the Plan and all Applicable Laws, and, in the case of a Committee, the specific duties delegated by the Board to such
Committee, and subject to the approval of any relevant authorities, the Administrator shall have the authority in its discretion: 
 (i) to determine the Fair Market Value; 
 (ii) to select the Service Providers to
whom Awards may from time to time be granted hereunder; 

  
 -4-

 (iii) to determine the number of Shares to be covered by each such Award granted hereunder;

 (iv) to approve forms of agreements for use under the Plan; 

(v) to determine the terms and conditions of any Award granted hereunder. Such terms and conditions include, but are not limited to, the
exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Common Stock
relating thereto, based in each case on such factors as the Administrator, in its sole discretion, shall determine; 
 (vi)
subject to the ASX Listing Rules, to institute, and determine the terms and conditions of, an Exchange Program; 
 (vii) to
prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under
applicable foreign laws; 
 (viii) to allow Optionees to satisfy withholding tax obligations as prescribed in Section 14;

 (ix) subject to the ASX Listing Rules, to modify or amend each Award (subject to Section 12 of the Plan) including but
not limited to the discretionary authority to extend the post-termination exercise period of Awards and to extend the maximum term of an Option (subject to Section 6(d) regarding Incentive Stock Options); 

(x) to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously
granted by the Administrator; and 
 (xi) to construe and interpret the terms of the Plan and Awards granted pursuant to the
Plan. 
 (c) Effect of Administrator’s Decision. All decisions, determinations and interpretations of
the Administrator shall be final and binding on all Optionees. 
 5. Eligibility. Nonstatutory Stock Options may be
granted to Service Providers. Incentive Stock Options may be granted only to Employees. 
 6. Stock Options. 

(a) Grant of Options. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may
grant Options in such amounts and for the class of Shares as the Administrator, in its sole discretion, will determine. 
 (b)
Option Agreement. Each Award of an Option will be evidenced by an Option Agreement that will specify the exercise price, the term of the Option, the number and class of Shares subject to the Option, the exercise restrictions, if any,
applicable to the Option, and such other terms and conditions as the Administrator, in its sole discretion, will determine. 

  
 -5-

 (c) Limitations. Each Option will be designated in the Option Agreement as either an
Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding such designation, however, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by
the Optionee during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as Nonstatutory Stock Options. For purposes of this Section 6(c),
Incentive Stock Options will be taken into account in the order in which they were granted, the Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted, and calculation will be performed in
accordance with Code Section 422 and Treasury Regulations promulgated thereunder. 
 (d) Term of Option. The term of
each Option will be stated in the Award Agreement; provided, however, that the term will be no more than ten (10) years from the date of grant thereof. In the case of an Incentive Stock Option granted to a Participant who, at the time the
Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five
(5) years from the date of grant or such shorter term as may be provided in the Award Agreement. 
 (e) Option Exercise
Price and Consideration. 
 (i) Exercise Price. The per Share exercise price for the Shares to be issued pursuant to
the exercise of an Option will be determined by the Administrator, but will be no less than one hundred percent (100%) of the Fair Market Value of the applicable Shares per Share on the date of grant. In addition, in the case of an Incentive
Stock Option granted to an Employee who owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred
ten percent (110%) of the Fair Market Value of the applicable Shares per Share on the date of grant. Notwithstanding the foregoing provisions of this Section 6(e)(i), Options may be granted with a per Share exercise price of less than one
hundred percent (100%) of the Fair Market Value of the applicable Shares per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Code Section 424(a). 

(ii) Waiting Period and Exercise Dates. At the time an Option is granted, the Administrator will fix the period within which the
Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised. 
 (iii)
Form of Consideration. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable
form of consideration at the time of grant. Such consideration may consist entirely of: (1) cash; (2) check; (3) wire transfer; (4) promissory note, to the extent permitted by Applicable Laws, (5) other Shares, provided that
such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided further that 

  
 -6-

 
accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (6) consideration received by the Company
under cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan; (7) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable
Laws, or (8) any combination of the foregoing methods of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance of such consideration may be reasonably expected to benefit
the Company. 
 (f) Exercise of Option. 
 (i) Procedure for Exercise; Rights as a Stockholder. Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by
the Administrator and set forth in the Option Agreement. An Option may not be exercised for a fraction of a Share. 
 An Option
will be deemed exercised when the Company receives: (i) notice of exercise (in such form as the Administrator may specify from time to time) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect
to which the Option is exercised (together with applicable tax withholding). Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Option Agreement and the Plan. For the avoidance of
doubt, the Administrator may, in its sole discretion, accept exercises that are contingent on specified time(s), events(s) and/or condition(s). Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested
by the Participant, in the name of the Participant and his or her spouse. Shares issued upon exercise of an Option may be issued subject to restriction on transfer of the Shares in Australia for a maximum period of 12 months as determined by the
Administrator at the time of issue of the Shares. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends, to
participate in new issues, or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the
Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 8 of the Plan. 

Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale
under the Option, by the number of Shares as to which the Option is exercised. 
 (ii) Termination of Relationship as a
Service Provider. If a Participant ceases to be a Service Provider, other than upon the Participant’s termination as the result of the Participant’s death or Disability, the Participant may exercise his or her Option within thirty
(30) days of termination, or such longer period of time as is specified in the Award Agreement or in writing by the Administrator (but in no event later than the expiration of the term of such Option as set forth in the Option Agreement) to the
extent that the Option is vested on the date of termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of
the Option will 

  
 -7-

 
revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by
such Option will revert to the Plan. 
 (iii) Disability of Participant. If a Participant ceases to be a Service
Provider as a result of the Participant’s Disability, the Participant may exercise his or her Option within six (6) months of termination, or such longer period of time as is specified in the Award Agreement (but in no event later than the
expiration of the term of such Option as set forth in the Option Agreement) to the extent the Option is vested on the date of termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as
to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and
the Shares covered by such Option will revert to the Plan. 
 (iv) Death of Participant. If a Participant dies while a
Service Provider, the Option may be exercised within six (6) months following the Participant’s death, or within such longer period of time as is specified in the Award Agreement (but in no event later than the expiration of the term of
such Option as set forth in the Option Agreement) to the extent that the Option is vested on the date of death, by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to the Participant’s death in
a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option is
transferred pursuant to the Participant’s will or in accordance with the laws of descent and distribution. If the Option is exercised pursuant to this Section 6(f)(iv), Participant’s designated beneficiary or personal representative
shall be subject to the terms of this Plan and the Award Agreement, including but not limited to the restrictions on transferability and forfeitability applicable to the Service Provider. Unless otherwise provided by the Administrator, if at the
time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will
terminate, and the Shares covered by such Option will revert to the Plan. 
 7. Limited Transferability of Awards. Unless
determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, or otherwise transferred in any manner other than by will or by the laws of descent and distribution, and may be exercised, during the lifetime of
the Optionee, only by the Optionee. If the Administrator makes an Award transferable, such Award may only be transferred (i) by will, (ii) by the laws of descent and distribution, or (iii) as permitted by Rule 701 of the Securities
Act. 

  
 -8-

 8. Adjustments; Dissolution or Liquidation; Merger or Change in Control. 

(a) Adjustments. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or
other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate
structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, shall adjust the number and class of Shares
that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award in accordance with Applicable Laws, including the ASX Listing Rules. 

(b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator shall
notify each Optionee as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.

 (c) Merger or Change in Control. In the event of a merger or Change in Control, each outstanding Award will be treated
as the Administrator determines (subject to the provisions of this Section 8(c)) without a Participant’s consent, including, without limitation, that (i) Awards will be assumed, or substantially equivalent Awards will be substituted,
by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant’s Awards will terminate upon
or immediately prior to the consummation of such merger or Change in Control; (iii) outstanding Awards will vest and become exercisable, in whole or in part prior to or upon consummation of such merger or Change in Control, and, to the extent
the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or Change in Control; (iv) (A) the termination of an Award in exchange for an amount of cash and/or property, if any, equal to the amount
that would have been attained upon the exercise of such Award as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Administrator determines in good faith
that no amount would have been attained upon the exercise of such Award or realization of the Participant’s rights, then such Award may be terminated by the Company without payment), or (B) the replacement of such Award with other rights
or property selected by the Administrator in its sole discretion; or (v) any combination of the foregoing. In taking any of the actions permitted under this subsection 8(c), the Administrator will not be obligated to treat all Awards, all
Awards held by a Participant, or all Awards of the same type, similarly. 
 In the event the successor corporation does not
assume or substitute for the Award (or portion thereof), the Participant will fully vest in and have the right to exercise all of his or her outstanding Options, including Shares as to which such Awards would not otherwise be vested or exercisable,
and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met. In addition, if an Option
is not assumed or substituted in the event of a merger or Change in Control, the Administrator will notify the Participant in writing or electronically that the Option will be exercisable for a period of time determined by the Administrator in its
sole discretion, and the Option will terminate upon the expiration of such period. 

  
 -9-

 For the purposes of this subsection 8(c), an Award will be considered assumed if, following
the merger or Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other securities or property)
received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority
of the outstanding Shares); provided, however, that if such consideration received in the merger or Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor
corporation, provide for the consideration to be received upon the exercise of an Option, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share
consideration received by holders of Common Stock in the merger or Change in Control. 
 Notwithstanding anything in this
Section 8(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the
Participant’s consent; provided, however, a modification to such performance goals only to reflect the successor corporation’s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.

 Notwithstanding anything in this Section 8(c) to the contrary, if a payment under an Award Agreement is subject to Code
Section 409A and if the change in control definition contained in the Award Agreement does not comply with the definition of “change of control” for purposes of a distribution under Code Section 409A, then any payment of an
amount that is otherwise accelerated under this Section will be delayed until the earliest time that such payment would be permissible under Code Section 409A without triggering any penalties applicable under Code Section 409A. 

(d) Tax Withholding. Prior to the delivery of any Shares pursuant to an Award (or exercise thereof), the Company shall have the
power and the right to deduct or withhold, or require a Optionee to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Optionee’s FICA obligation) required to be withheld with
respect to such Award (or exercise thereof). The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Optionee to satisfy such tax withholding obligation, in whole or in part by
(without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, (iii) delivering to the Company
already-owned Shares having a Fair Market Value equal to the statutory amount required to be withheld, provided the delivery of such Shares will not result in any adverse accounting consequences, as the Administrator determines in its sole
discretion, or (iv) selling a sufficient number of Shares otherwise deliverable to the Optionee through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to
be withheld. The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or
local marginal income tax rates applicable to the Optionee with respect to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the
date that the taxes are required to be withheld. 

  
 -10-

 9. Leaves of Absence. 

(a) Unless the Administrator provides otherwise, the vesting of Options granted hereunder shall be suspended during
any unpaid leave of absence. A Participant shall not cease to be an Employee in the case of (A) any leave of absence approved by the Company or (B) transfers between locations of the Company or between the Company, its Parent, any
Subsidiary, or any successor. For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave
of absence approved by the Company is not so guaranteed, then six (6) months following the first (1st) day of such leave, any Incentive Stock Option held by the Optionee shall cease to be treated as an Incentive Stock Option and shall be treated for tax purposes as a Nonstatutory Stock Option.

 10. Time of Granting Awards. The date of grant of an Award shall, for all purposes, be the date on
which the Administrator makes the determination granting such Award, or such later date as is determined by the Administrator. Notice of the determination shall be given to each Service Provider to whom an Award is so granted within a reasonable
time after the date of such grant. 
 11. Term of Plan. Subject to Section 16 of the Plan, the Plan will become
effective upon its adoption by the Board. Unless sooner terminated under Section 12, it will continue in effect for a term of ten (10) years from the later of (a) the effective date of the Plan, or (b) the earlier of the most
recent Board or stockholder approval of an increase in the number of Shares reserved for issuance under the Plan. 
 12.
Amendment and Termination of the Plan. 
 (a) Amendment and Termination. The Board may at
any time amend, alter, suspend or terminate the Plan. 
 (b) Shareholder Approval. The Board shall obtain shareholder
approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws. 
 (c)
Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan shall impair the rights of any Optionee, unless mutually agreed otherwise between the Optionee and the Administrator,
which agreement must be in writing (which may include e-mail) and signed by the Optionee and the Company. Termination of the Plan shall not affect the Administrator’s ability to exercise the powers granted to it hereunder with respect to Awards
granted under the Plan prior to the date of such termination. 
 13.
Conditions Upon Issuance of Shares. 
 (a) Legal Compliance. Shares shall not be issued
pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares shall comply with Applicable Laws and shall be further subject to the approval of counsel for the Company with respect to such
compliance. 

  
 -11-

 (b) Investment Representations. As a condition to the exercise of an Award, the
Administrator may in its discretion require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute
such Shares if, in the opinion of counsel for the Company, such a representation is required. 
 14. Inability to Obtain
Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall
relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained. 
 15. Reservation of Shares. The Company, during the term of this Plan, shall at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the
requirements of the Plan. 
 16. Shareholder Approval. The Plan shall be subject to approval by the shareholders of the
Company within twelve (12) months after the date the Plan is adopted. Such shareholder approval shall be obtained in the degree and manner required under Applicable Laws. 
 17. Compliance With Code Section 409A. Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Code
Section 409A, except as otherwise determined in the sole discretion of the Administrator. The Plan and each Award agreement under the Plan is intended to meet the requirements of Code Section 409A and will be construed and interpreted
in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A, the Award will be
granted, paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code
Section 409A. 

  
 -12-

 AUDEO ONCOLOGY, INC. 

2012 STOCK PLAN 
 OPTION AGREEMENT 
 Unless otherwise defined herein, the terms defined in
the Audeo Oncology, Inc. 2012 Stock Plan (the “Plan”) will have the same defined meanings in this Option Agreement (the “Option Agreement”). 
  

	I.	NOTICE OF STOCK OPTION GRANT 

 Participant Name: 
 Address: 

You have been granted an Option to purchase Common Stock of Audeo Oncology, Inc. (the “Company”), subject to the terms and
conditions of the Plan and this Option Agreement, as follows: 
  

							
	Grant Number	 	  
	  	
			
	Date of Grant	 	  
	  	
			
	Vesting Commencement Date	 	  
	  	
				
	Exercise Price per Share	 	$	 	  
	  	
			
	Total Number of Shares Granted	 	  
	  	
				
	Total Exercise Price	 	$	 	  
	  	
				
	Type of Option:	 		 	Incentive Stock Option	  	
				
		 		 	Nonstatutory Stock Option	  	
			
	Term/Expiration Date:	 	  
	  	

 Vesting Schedule: 
 Subject to any acceleration provisions contained in the Plan or set forth below, this Option may be exercised, in whole or in part, in accordance with the following schedule: 

Twenty-five percent (25%) of the Shares subject to the Option shall vest on the one (1) year anniversary of
the Vesting Commencement Date, and one forty-eighth
(1/48th) of the Shares subject to the Option shall
vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to Participant continuing to be a Service Provider through each such date.

 Termination Period: 

This Option will be exercisable for three (3) months after Participant ceases to be a Service Provider, unless such termination is
due to Participant’s death or Disability, in which case this Option will be exercisable for twelve (12) months after Participant ceases to be Service Provider. Notwithstanding the foregoing, in no event may this Option be exercised after
the Term/Expiration Date as provided above and may be subject to earlier termination as provided in Section 13 of the Plan. 
 By Participant’s signature and the signature of the Company’s representative below, Participant and the Company agree that this Option is granted under and governed by the terms and conditions
of the Plan and this Option Agreement, including the Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, all of which are made a part of this document. Participant has reviewed the Plan and this Option Agreement in their
entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option Agreement and fully understands all provisions of the Plan and Option Agreement. Participant hereby agrees to accept as binding, conclusive and final all
decisions or interpretations of the Administrator upon any questions relating to the Plan and Option Agreement. Participant further agrees to notify the Company upon any change in the residence address indicated below. 

 

					
	PARTICIPANT:	 		 	AUDEO ONCOLOGY, INC.
			
	  
	 		 	  

	Signature	 		 	By
			
	  
	 		 	  

	Print Name	 		 	Title
			
	Residence Address:	 		 	
			
	  
	 		 	
			
	  
	 		 	

 EXHIBIT A 

TERMS AND CONDITIONS OF STOCK OPTION GRANT 
 A. Grant of Option. The Company hereby grants to the Participant named in the Notice of Grant attached as Part I of this Option Agreement (the “Participant”) an option (the
“Option”) to purchase the number of Shares, as set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the “Exercise Price”), subject to all of the terms and conditions in this Option
Agreement and the Plan, which is incorporated herein by reference. Subject to Section 12 of the Plan, in the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Option Agreement, the terms and
conditions of the Plan will prevail. 
 If designated in the Notice of Grant as an Incentive Stock Option (“ISO”),
this Option is intended to qualify as an ISO under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). However, if this Option is intended to be an ISO, to the extent that it exceeds the $100,000 rule of Code
Section 422(d) it will be treated as a Nonstatutory Stock Option (“NSO”). Further, if for any reason this Option (or portion thereof) will not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion
thereof) shall be regarded as a NSO granted under the Plan. In no event will the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to
the failure of the Option to qualify for any reason as an ISO. 
 B. Vesting Schedule. Except as provided in
Section 3, the Option awarded by this Option Agreement will vest in accordance with the vesting provisions set forth in the Notice of Grant. Shares scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest
in Participant in accordance with any of the provisions of this Option Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs. 

C. Administrator Discretion. The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser
portion of the balance, of the unvested Option at any time, subject to the terms of the Plan. If so accelerated, such Option will be considered as having vested as of the date specified by the Administrator. 

D. Exercise of Option. 
 (a) Right to Exercise. This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this
Option Agreement. 
 (b) Method of Exercise. This Option is exercisable by delivery of an exercise notice, in the form
attached as Exhibit B (the “Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which will state the election to exercise the Option, the number of Shares in respect of which the
Option is being exercised (the “Exercised Shares”), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice will be completed by Participant and delivered
to the Company. The Exercise Notice will be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares together with any applicable tax withholding. This Option will be deemed to be exercised upon receipt by the Company of
such fully executed Exercise Notice accompanied by such aggregate Exercise Price. 

 E. Method of Payment. Payment of the aggregate Exercise Price will be by any of the
following, or a combination thereof, at the election of Participant. 
 (a) cash; 

(b) check; 

(c) consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or

 (d) surrender of other Shares which have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price
of the Exercised Shares, provided that accepting such Shares, in the sole discretion of the Administrator, will not result in any adverse accounting consequences to the Company. 

F. Tax Obligations. 
 (a) Withholding Taxes. Notwithstanding any contrary provision of this Option Agreement, no certificate representing the Shares will be issued to Participant, unless and until satisfactory
arrangements (as determined by the Administrator) will have been made by Participant with respect to the payment of income, employment and other taxes which the Company determines must be withheld with respect to such Shares. To the extent
determined appropriate by the Company in its discretion, it will have the right (but not the obligation) to satisfy any tax withholding obligations by reducing the number of Shares otherwise deliverable to Participant. If Participant fails to make
satisfactory arrangements for the payment of any required tax withholding obligations hereunder at the time of the Option exercise, Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver Shares if
such withholding amounts are not delivered at the time of exercise. 
 (b) Notice of Disqualifying Disposition of ISO
Shares. If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Grant Date,
or (ii) the date one (1) year after the date of exercise, Participant will immediately notify the Company in writing of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company on the
compensation income recognized by Participant. 
 (c) Code Section 409A. Under Code Section 409A, an option
that vests after December 31, 2004 (or that vested on or prior to such date but which was materially modified after October 3, 2004) that was granted with a per Share exercise price that is determined by the Internal Revenue Service (the
“IRS”) to be less than the Fair Market Value of a Share on the date of grant (a “Discount Option”) may be considered “deferred compensation.” A Discount Option may result in (i) income recognition by Participant
prior to the exercise of the option, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges. The Discount Option may also result in additional state income, penalty and interest
charges to the Participant. Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share on the Date of Grant in a
later examination. Participant agrees that if the IRS determines that the 

 
Option was granted with a per Share exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant will be solely responsible for Participant’s costs
related to such a determination. 
 G. Rights as Stockholder. Neither Participant nor any person claiming under or
through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares will have been issued, recorded on the records of the
Company or its transfer agents or registrars, and delivered to Participant. After such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of
dividends and distributions on such Shares and participation in new issues. Shares issued upon the exercise of an Option may be issued subject to restriction on transfer of the Shares in Australia for a maximum period of 12 months as determined by
the Administrator at the time of issue of the Shares. 
 H. No Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES
AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF
BEING HIRED, BEING GRANTED THE OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN
EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY
EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 
 I. Address for Notices. Any notice to be given to the Company under the terms of this Option Agreement will be addressed to the Company, in care of its Stock Administration at Audeo Oncology, Inc.,
100 Pine Street, Suite 2040, San Francisco, California 94111, or at such other address as the Company may hereafter designate in writing. 
 J. Non-Transferability of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of
Participant only by Participant. 
 K. Binding Agreement. Subject to the limitation on the transferability of this grant
contained herein, this Option Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. 

L. Additional Conditions to Issuance of Stock. If at any time the Company will determine, in its discretion, that the listing,
registration or qualification of the Shares or interests in the Shares upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory authority is necessary or desirable as a condition to
the issuance of Shares to Participant (or his or her estate), such issuance will not occur unless and until such listing, registration, qualification, consent or approval will have been effected or obtained free of any conditions not acceptable to
the Company. The Company will make all reasonable efforts to meet 

 
the requirements of any such state or federal law or securities exchange and to obtain any such consent or approval of any such governmental authority. Assuming such compliance, for income tax
purposes the Exercised Shares will be considered transferred to Participant on the date the Option is exercised with respect to such Exercised Shares. 
 M. Plan Governs. This Option Agreement is subject to all terms and provisions of the Plan. In the event of a conflict between one or more provisions of this Option Agreement and one or more
provisions of the Plan, the provisions of the Plan will govern. Capitalized terms used and not defined in this Option Agreement will have the meaning set forth in the Plan. 
 N. Administrator Authority. The Administrator will have the power to interpret the Plan and this Option Agreement and to adopt such rules for the administration, interpretation and application of
the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject to the Option have vested). All actions taken and all interpretations and
determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons. No member of the Administrator will be personally liable for any action, determination or interpretation
made in good faith with respect to the Plan or this Option Agreement. 
 O. Electronic Delivery. The Company may, in its
sole discretion, decide to deliver any documents related to Options awarded under the Plan or future options that may be awarded under the Plan by electronic means or request Participant’s consent to participate in the Plan by electronic means.
Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 P. Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or
construction of this Option Agreement. 
 Q. Agreement Severable. In the event that any provision in this Option
Agreement will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Option Agreement. 

R. Modifications to the Agreement. This Option Agreement constitutes the entire understanding of the parties on the subjects
covered. Participant expressly warrants that he or she is not accepting this Option Agreement in reliance on any promises, representations, or inducements other than those contained herein. Modifications to this Option Agreement or the Plan can be
made only in an express written contract executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Option Agreement, the Company reserves the right to revise this Option Agreement as it deems
necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Code Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Code Section 409A in connection to
this Option. 
 S. Amendment, Suspension or Termination of the Plan. By accepting this Option, Participant expressly
warrants that he or she has received an Option under the Plan, and has received, read and understood a description of the Plan. Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the
Company at any time. 

 T. Governing Law. This Option Agreement will be governed by the laws of the State of
California, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this Option or this Option Agreement, the parties hereby submit to and consent to the jurisdiction of the State of
California, and agree that such litigation will be conducted in the courts of San Francisco County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this Option is made
and/or to be performed. 

 EXHIBIT B 

AUDEO ONCOLOGY, INC. 
 2012 STOCK PLAN 
 EXERCISE NOTICE 

Audeo Oncology, Inc. 
 100 Pine Street, Suite
2040 
 San Francisco, CA 94111 

Attention: Chief Financial Officer 
 A. Exercise of Option. Effective as of today,             ,         , the undersigned
(“Purchaser”) hereby elects to purchase                          shares (the “Shares”) of the Common Stock of
Audeo Oncology, Inc. (the “Company”) under and pursuant to the 2012 Stock Plan (the “Plan”) and the Stock Option Agreement dated
                     (the “Option Agreement”). The purchase price for the Shares will be $        ,
as required by the Option Agreement. 
 B. Delivery of Payment. Purchaser herewith delivers to the Company the full
purchase price of the Shares and any required tax withholding to be paid in connection with the exercise of the Option. 
 C.
Representations of Purchaser. Purchaser acknowledges that Purchaser has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. 

D. Rights as Stockholder. Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly
authorized transfer agent of the Company) of the Shares, no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to the Option, notwithstanding the exercise of the Option. The Shares
so acquired will be issued to Purchaser as soon as practicable after exercise of the Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance, except as provided in Section 8 of
the Plan. 
 E. Tax Consultation. Purchaser understands that Purchaser may suffer adverse tax consequences as a result of
Purchaser’s purchase or disposition of the Shares. Purchaser represents that Purchaser has consulted with any tax consultants Purchaser deems advisable in connection with the purchase or disposition of the Shares and that Purchaser is not
relying on the Company for any tax advice. 

 F. Entire Agreement; Governing Law. The Plan and Option Agreement are incorporated
herein by reference. This Exercise Notice, the Plan and the Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the
Company and Purchaser with respect to the subject matter hereof, and may not be modified adversely to the Purchaser’s interest except by means of a writing signed by the Company and Purchaser. This agreement is governed by the internal
substantive laws, but not the choice of law rules, of the State of California. 
  

					
	Submitted by:	 		 	Accepted by:
			
	PURCHASER:	 		 	AUDEO ONCOLOGY, INC.
			
	  
	 		 	  

	Signature	 		 	By
			
	  
	 		 	  

	Print Name	 		 	Title
			
	Residence Address:	 		 	
			
	  
	 		 	
			
	  
	 		 	
			
		 		 	  

		 		 	Date Received

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]